Risperidon vs. other antipsychotics in schizophrenia: The assessment of patients' attitudes

Psychiatria Danubina

Volumn 16, Issue 3, 2004, Pages 127-131

  Jasovic Gasic, Miroslava ^a   Marić, Nadja ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

First generation antipsychotics; Patients' attitudes; Schizophrenia; Second generation antipsychotics

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; THIORIDAZINE;

ADULT; AKATHISIA; ANAMNESIS; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT SATISFACTION; QUESTIONNAIRE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 5144224422     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bobes J, Rejas J & Garcia-Garcia M: Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003; 62:77-88
2. Chakos M; Lieberman J, Hoffman E, Bratford D & Sheitman B: Effectiveness of second generation antipsychotics in patients with treatment-resistant schizophrenia: a review of meta-analysis of randomized trials. Am J Psychiatry 2001; 158:518-26
3. Csernansky JR, Mahmoud R & Brenner R: A comparison of risperidone and haloperidol in the prevention of relapse in patients with schizophrenia. New Engl J Med 2002; 346:16-22
4. Davis JM, Chen N & Glick ID: A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64
5. Fleischhacker WW, Oehl MA & Hummer M: Factors influencing compliance in schizophrenia. J Clin Psychiatry 2003; 64(suppl 16):10-3
6. Geddes J, Freemantle N, Harrison P & Bebbington P: Atypical antipsychotic in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 231:1371-6
7. Jakovljević M, Dossenbach MR, Friedel P, Schausberger B, Grundy SL, Hotujac L et al: Olanzapine versus flufenazine in the acute (6-weeks) treatment of schizophrenia. Psychiatria Danubina 1999; 11:3-11
8. Kay SR, Fiszbein A & Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76
9. Lindenmayer JP, Nathan AM & Smith RC: Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(suppl 23):30-8
10. Marić N, Zogović T, Djordjević A, Jašović-Gašić M & Paunović VR: First-Line Therapy for Schizophrenia at University Psychiatric Hospital in Belgrade European Neuropsychopharmacol 2001: Suppl 3: 11: S295
11. Mukherjee S, Decina P, Bocola V, Saraceni F & Scapicchio PL: Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996; 37:68-73
12. Wieck A & Haddad PM: Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry. 2003; 182:199-204
13. World Health Organization: International Classification of Diseases, 10th edition. Geneva: WHO, 1994